

Eric P Winer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6615708/eric-p-winer-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200
papers

23,278
citations

65
h-index

152
g-index

212
ext. papers

30,320
ext. citations

10.3
avg, IF

7.06
L-index

#	Paper	IF	Citations
200	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2108-2121	59.2	1871
199	Breast Cancer Treatment: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 288-304	39.4	1202
198	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748	59.2	975
197	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 971-7	59.2	766
196	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1145-53	2.2	734
195	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2382-7	2.2	695
194	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017 , 548, 471-475	50.4	618
193	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 13-21	2.2	590
192	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015 , 5, 1164-1177	24.4	581
191	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3744-52	2.2	572
190	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2255-69	2.2	545
189	Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2875-82	2.2	521
188	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 107-18	59.2	500
187	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 134-41	59.2	455
186	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3764-73	12.9	438
185	Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3483-9	2.2	437
184	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. <i>Lancet Oncology</i> , 2014 , 15, 1207-14	21.7	432

183	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 44-59	21.7	422
182	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 597-609	59.2	396
181	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016 , 375, 209-19	59.2	364
180	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016 , 529, 413-417	50.4	363
179	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. <i>Cancer</i> , 2012 , 118, 5463-72	6.4	343
178	Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 1073-81	27.4	318
177	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017 , 8, 1324	17.4	314
176	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1460-8	2.2	290
175	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1902-9	2.2	281
174	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 122-137	59.2	270
173	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2078-99	2.2	270
172	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3234-41	2.2	264
171	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016 , 29, 255-269	24.3	244
170	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 542-9	2.2	242
169	Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3699-704	2.2	226
168	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019 , 37, 423-438	2.2	218
167	Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 884-890	2.2	217
166	Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3840-7	2.2	212

165	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3308-14	2.2	195
164	Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. <i>Cancer</i> , 1998 , 83, 1362-8	6.4	184
163	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1689-701	2.2	179
162	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2254-61	2.2	170
161	CDK4/6 inhibition in breast cancer: current practice and future directions. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918786451	5.4	167
160	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1057-65	4.4	166
159	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017 , 35, 1061-1069	2.2	164
158	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2361-9	2.2	157
157	Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2142-50	2.2	155
156	Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 701-8	2.2	142
155	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. <i>Cancer Cell</i> , 2018 , 33, 173-186.e5	24.3	133
154	Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2100-8	2.2	129
153	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016 , 34, 945-52	2.2	121
152	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1868-1875	2.2	120
151	Neratinib Efficacy and Circulating Tumor DNA Detection of Mutations in Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5687-5695	12.9	119
150	Olaparib and Specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , 2019 , 20, 570-580	21.7	118
149	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 543-553	2.2	113
148	Phase II evaluation of thalidomide in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2710-7	2.2	99

147	Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. <i>Nature Genetics</i> , 2019 , 51, 207-216	36.3	94
146	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4274-4282	2.2	92
145	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2772-9	2.2	91
144	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1008-1008	2.2	82
143	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016 , 34, 2602-9	2.2	77
142	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016 , 22, 723-6	50.5	76
141	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019 , 21, 78	8.3	75
140	Tumor Mutational Burden and Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2565-2572	12.9	71
139	Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4071-6	2.2	69
138	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 499-511	21.7	68
137	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 1174-1193	24.4	67
136	Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer: CALGB 40202 (Alliance). <i>Journal of Clinical Oncology</i> , 2017 , 35, 1008-1008	2.2	66
135	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3809-15	3.1	65
134	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , 2021 , 22, 212-222	21.7	64
133	Randomized trial of a physical activity intervention in women with metastatic breast cancer. <i>Cancer</i> , 2016 , 122, 1169-77	6.4	63
132	Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 2311-7	2.2	60
131	Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2318-27	2.2	60
130	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2804-2807	2.2	59

129	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018 , 4, 10	7.8	58
128	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016 , 2,	7.8	58
127	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. <i>Oncologist</i> , 2017 , 22, 25-32	5.7	56
126	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1005-1016	9.7	56
125	Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3249-59	12.9	54
124	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. <i>Clinical Cancer Research</i> , 2018 , 24, 1795-1804	12.9	52
123	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019 , 25, 2975-2987	12.9	51
122	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 29-36	13.4	48
121	Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 40, 335-41	3.5	48
120	Phase 2 study of pembrolizumab as first-line therapy for PD-L1 β positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1088-1088	2.2	47
119	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 316	27.4	46
118	F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017 , 23, 3053-3060	12.9	45
117	Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). <i>Journal of Oncology Practice</i> , 2014 , 10, e285-92	3.1	45
116	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
115	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 297-304	4.4	42
114	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4644-4655	12.9	41
113	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5292-5304	12.9	41
112	Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. <i>Cancer</i> , 2008 , 112, 700-709	6.4	41

111	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015 , 33, 1108-14	4.3	39
110	Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1465-73	2.2	39
109	IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1003-1003	2.2	39
108	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5974-5989	12.9	37
107	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	33
106	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2556-2564	12.9	32
105	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016 , 22, 6039-6050	12.9	32
104	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2623-31	2.2	31
103	Perils of the Pathologic Complete Response. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3959-3962	2.2	30
102	Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. <i>Cancer</i> , 2005 , 104, 1580-9	6.4	29
101	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4184-4193	2.2	28
100	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1598-1605	13.4	28
99	Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. <i>Psycho-Oncology</i> , 1999 , 8, 167-76	3.9	27
98	TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1002-1002	2.2	27
97	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 305-312	4.4	27
96	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018 , 20, 109	8.3	27
95	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 714-722	2.2	26
94	Breast cancer-specific survival by age: Worse outcomes for the oldest patients. <i>Cancer</i> , 2018 , 124, 2184-2191	11.1	26

93	SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	26
92	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, 238-245	3	24
91	Quality-of-life research in patients with breast cancer. <i>Cancer</i> , 1994 , 74, 410-5	6.4	23
90	Androgen Receptor Expression and Breast Cancer Survival: Results From the NursesQHealth Studies. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 700-708	9.7	23
89	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 120	8.3	22
88	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	21
87	Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. <i>Breast</i> , 2015 , 24 Suppl 2, S132-5	3.6	20
86	Heterogeneity of breast cancer and implications of adjuvant chemotherapy. <i>Breast Cancer</i> , 2008 , 15, 31-4	3.4	20
85	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2375-2385	2.2	20
84	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) 2020 ,		19
83	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1013-1013	2.2	18
82	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 942-950	59.2	18
81	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021 , 11, 2474-2487	24.4	17
80	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 504-504	2.2	16
79	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019 , 19, 399-404	3	15
78	Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. <i>Clinical Breast Cancer</i> , 2014 , 14, 413-6	3	15
77	Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. <i>JAMA Oncology</i> , 2017 , 3, 402-409	13.4	14
76	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 500-500	2.2	14

75	Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. <i>Oncologist</i> , 2019 , 24, e441-e449	5.7	13
74	Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4280-6	3.1	13
73	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021 , 2, 34-48	15.4	13
72	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015 , 20, 713-8	5.7	11
71	Informed consent for BRCA1 and BRCA2 testing. <i>Breast Disease</i> , 1998 , 10, 99-114	1.6	11
70	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2021 , JCO2102554	2.2	11
69	Genomic Characterization of Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1105-1118	12.9	11
68	A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. <i>Journal of Geriatric Oncology</i> , 2013 , 4, 353-61	3.6	10
67	Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. <i>Breast Disease</i> , 2001 , 14, 41-50	1.6	10
66	De-escalating Breast Cancer Surgery-Where Is the Tipping Point?. <i>JAMA Oncology</i> , 2020 , 6, 183-184	13.4	10
65	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6149-6157	12.9	10
64	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020 , 20, 145-151.e2	3	10
63	Timeliness in Breast Cancer Treatment-The Sooner, the Better. <i>JAMA Oncology</i> , 2016 , 2, 302-4	13.4	9
62	A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1046-1046	2.2	9
61	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 113-123	4.4	9
60	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 983-991	12.9	9
59	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 303-310	4.4	8
58	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz096	4.6	8

57	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2015 , 20, 992-1000	5.7	8
56	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1143-1155	9.7	8
55	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. <i>Cancer</i> , 2015 , 121, 1937-48	6.4	7
54	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101506	2.2	7
53	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4120-4129	2.2	7
52	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020 , 13, 1055-1062	3.2	7
51	Breast cancer: T-DM1 - an important agent in the history of breast cancer management. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 651-652	19.4	6
50	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1005-1005	2.2	6
49	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 355-359	9.7	6
48	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017 , 224, 688-694	4.4	5
47	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	5
46	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021 , 7, 110	7.8	5
45	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. <i>Breast</i> , 2016 , 30, 136-140	3.6	4
44	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. <i>JAMA Oncology</i> , 2021 , 7, 609-615	13.4	4
43	Temporal and spatial topography of cell proliferation in cancer.. <i>Nature Cell Biology</i> , 2022 , 24, 316-326	23.4	4
42	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. <i>Clinical Breast Cancer</i> , 2020 , 20, 395-401.e3	3	3
41	Predicting breast cancer therapeutic response. <i>Nature Medicine</i> , 2018 , 24, 535-537	50.5	3
40	Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 68-72	3.5	3

39	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100896	2.2	3
38	Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022 ,	4	3
37	Perceptions of patients with early stage breast cancer toward research biopsies. <i>Cancer</i> , 2021 , 127, 12086-12193	12.19	3
36	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. <i>JCI Insight</i> , 2021 , 6,	9.9	3
35	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 215-227	4.4	3
34	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2247-2256	2.2	3
33	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2720-2731	2.2	3
32	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021 , 12, 5563	17.4	3
31	Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature. <i>Cancer Treatment Communications</i> , 2015 , 4, 41-45		2
30	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 316-324	7.3	2
29	Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. <i>New England Journal of Medicine</i> , 2007 , 357, 1640-8	59.2	2
28	Genomic features of rapid versus late relapse in triple negative breast cancer. <i>BMC Cancer</i> , 2021 , 21, 568	4.8	2
27	Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119 2021 ,		2
26	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ-Reply. <i>JAMA Oncology</i> , 2020 , 6, 1118	13.4	2
25	p16-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases.. <i>Nature Communications</i> , 2022 , 13, 1473	17.4	2
24	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 2145-2156	5.6	1
23	Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 443-445	9.7	1
22	The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	1

21	ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS600-TPS600	2.2	1
20	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	1
19	Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1 ⁺ metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS1106-TPS1106	7.2	1
18	ALEXANDRA/Impassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS597-TPS597	2.2	1
17	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 98	7.8	1
16	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. <i>Leukemia</i> , 2021 ,	10.7	1
15	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, e20-e26		1
14	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, 45-52	4	1
13	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab025	4.6	0
12	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS1102-TPS1102	2.2	0
11	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2 ⁻ breast cancer. <i>Cancer Research</i> , 2022 , 82, GS2-01-GS2-01	10.1	0
10	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.. <i>Npj Breast Cancer</i> , 2022 , 8, 18	7.8	0
9	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 63	7.8	0
8	Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1746-1747	2.2	
7	Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 514-514	2.2	
6	Genomic profiling of breast cancer brain metastases reveals targetable alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2525-2525	2.2	
5	Expanding criteria for prognostic stage IA disease in HR+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 550-550	2.2	
4	Temporal and spatial topography of cell proliferation in cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3122-3122	2.2	

- 3 Survival in male breast cancer (MaBC) over the past three decades.. *Journal of Clinical Oncology*, **2021**, 39, 569-569 2.2
- 2 Reply to M. Tanaka et al. *Journal of Clinical Oncology*, **2021**, 39, 3648-3649 2.2
- 1 The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. *Clinical Advances in Hematology and Oncology*, **2008**, 6, 573-4 0.6